A Phase 2 Study of ET-743 in Subjects With Advanced Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 53
- 主要终点
- Number of patients with objective response in each treatment arm.
研究概览
简要总结
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced breast cancer.
详细描述
Patients will be enrolled in the study after all study specific-entry criteria are met and informed consent is obtained. Patients will be required to attend regular clinic visits to receive study medication and have their status monitored. Patients will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the study physician (Investigator) conducting this study. Trabectedin 580 mcg/m2 once weekly for 3 consecutive weeks (Treatment A) or 1,300 mcg/m2 once every 21 days (Treatment B) will be given to patients as a 3-hour intravenous (i.v). infusion via a central venous catheter which is a tube placed into a large vein that is used to administer medications. All patients will be given dexamethasone 10 mg i.v. 30 minutes before each trabectedin infusion. Patients may receive multiple cycles of trabectedin in the absence of disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of advanced breast cancer
- •Prior therapy with anthracycline and taxane (2 types of chemotherapy drugs)
- •At least one measureable tumor lesion
- •Adequate bone marrow, hepatic and renal function
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
排除标准
- •Known hypersensitivity to any components of the i.v. formulation of ET-743 or dexamethasone
- •Pregnant or lactating women
- •Known metastases (spread) of cancer to the central nervous system
- •History of another neoplastic disease unless in remission for five years or more.
研究组 & 干预措施
001
ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
干预措施: ET743 (Drug)
002
ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
干预措施: ET743 (Drug)
结局指标
主要结局
Number of patients with objective response in each treatment arm.
时间窗: Up to approximately 52 weeks
次要结局
- Progression-free survival (PFS)(Up to approximately 52 weeks)
- Time to progression (TTP)(Up to approximately 52 weeks)
- Overall survival (OS)(Up to approximately 52 weeks)
- The number of patients with treatment-emergent adverse events(Up to approximately 52 weeks)
- Concentrations of trabectedin in plasma as a measure of the pharmacokinetics of trabectedin(During the first two 28-day treatment cycles)